UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

The New England journal of medicine, 2017-01, Vol.376 (3), p.221-234

2017

Volltextzugriff (PDF)

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

The Lancet (British edition), 2008-06, Vol.371 (9630), p.2085-2092

2008

Volltextzugriff (PDF)

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis

European journal of neurology, 2018-02, Vol.25 (2), p.215-237

2018

Volltextzugriff (PDF)

Induction of human IL-10-producing neutrophils by LPS-stimulated Treg cells and IL-10

Mucosal immunology, 2016-03, Vol.9 (2), p.364-378

2016

Volltextzugriff (PDF)

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

Neurology, 2012-04, Vol.78 (14), p.1069

2012

Volltextzugriff (PDF)

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

Journal of neurology, 2014-04, Vol.261 (4), p.773-783

2014

Volltextzugriff (PDF)

Optical coherence tomography in multiple sclerosis: Thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy

Journal of neurology, 2008-10, Vol.255 (10), p.1555-1560

2008

Volltextzugriff (PDF)

Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004

European journal of neurology, 2004-09, Vol.11 (9), p.577-581

2004

Volltextzugriff (PDF)

cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity

Brain (London, England : 1878), 2003-05, Vol.126 (5), p.1048-1057

2003

Volltextzugriff (PDF)

Patients with multiple sclerosis resisted to glucocorticoid therapy: abnormal expression of heat-shock protein 90 in glucocorticoid receptor complex

Multiple sclerosis, 2008-08, Vol.14 (7), p.919-926

2008

Volltextzugriff (PDF)

Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing−remitting multiple sclerosis

European journal of neurology, 2016-02, Vol.23 (2), p.412-415

2016

Volltextzugriff (PDF)

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

Multiple sclerosis, 2010-11, Vol.16 (11), p.1360-1366

2010

Volltextzugriff (PDF)

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

The New England journal of medicine, 2017-01, Vol.376 (3), p.209-220

2017

Volltextzugriff (PDF)

EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses

European journal of neurology, 2005-12, Vol.12 (12), p.939-946

2005

Volltextzugriff (PDF)

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS

Neurology : neuroimmunology & neuroinflammation, 2015-04, Vol.2 (2), p.e65-e65

2015

Volltextzugriff (PDF)

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

The New England journal of medicine, 2010-02, Vol.362 (5), p.387-401

2010

Volltextzugriff (PDF)

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

Multiple sclerosis, 2018-02, Vol.24 (2), p.96-120

2018

Volltextzugriff (PDF)

Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b

Journal of neurology, 2008-04, Vol.255 (4), p.480-487

2008

Volltextzugriff (PDF)

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

The New England journal of medicine, 2015-10, Vol.373 (15), p.1418-1428

2015

Volltextzugriff (PDF)

Daclizumab HYP reduces total disability burden of patients with multiple sclerosis: results from an exploratory area under the curve analysis

Journal of the neurological sciences, 2015-10, Vol.357, p.e300-e301

2015

Volltextzugriff (PDF)

Anti-tumor necrosis factor therapy abrogates autoimmune demyelination

Annals of neurology, 1991-11, Vol.30 (5), p.694-700

1991

Volltextzugriff (PDF)

Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system

Annals of the rheumatic diseases, 2000-11, Vol.59 (suppl 1), p.i94-i102

Selmaj, Krzysztof W

2000

Volltextzugriff (PDF)

Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis

Clinical and experimental immunology, 2009-09, Vol.157 (3), p.332-342

2009

Volltextzugriff (PDF)

No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment

European journal of neurology, 2002-11, Vol.9 (6), p.565-572

2002

Volltextzugriff (PDF)

1 – 25 von 230

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(216)
Mit Volltextzugriff
(188)

Publikationsform

Sprache

Englisch
(214)
Japanisch
(15)
Polnisch
(15)
Russisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(118)
Science & Technology
(112)
Life Sciences & Biomedicine
(111)
Neurosciences & Neurology
(79)
Female
(78)
Adult
(71)
Multiple Sclerosis
(70)
Clinical Neurology
(66)
Male
(63)
Neurology
(63)
Biological And Medical Sciences
(59)
Medical Sciences
(51)
Middle Aged
(51)
Neurosciences
(46)
Magnetic Resonance Imaging
(36)
Animals
(34)
Double-Blind Method
(29)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(28)
Immunology
(25)
Brain - Pathology
(24)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis

Induction of human IL-10-producing neutrophils by LPS-stimulated Treg cells and IL-10

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

Optical coherence tomography in multiple sclerosis: Thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity

Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004

cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity

Patients with multiple sclerosis resisted to glucocorticoid therapy: abnormal expression of heat-shock protein 90 in glucocorticoid receptor complex

Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing−remitting multiple sclerosis

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Daclizumab HYP reduces total disability burden of patients with multiple sclerosis: results from an exploratory area under the curve analysis

Anti-tumor necrosis factor therapy abrogates autoimmune demyelination

Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system

Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis

No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment

Suchergebnisse filtern